Collaborative Drug Therapy Management and Comprehensive Medication Management―2015

<jats:p>The American College of Clinical Pharmacy (<jats:styled-content style="fixed-case">ACCP</jats:styled-content>) previously published position statements on collaborative drug therapy management (<jats:styled-content style="fixed-case">CDTM</jats:styled-content>) in 1997 and 2003. Since 2003, significant federal and state legislation addressing<jats:styled-content style="fixed-case">CDTM</jats:styled-content>has evolved and expanded throughout the United States.<jats:styled-content style="fixed-case">CDTM</jats:styled-content>is well suited to facilitate the delivery of comprehensive medication management (<jats:styled-content style="fixed-case">CMM</jats:styled-content>) by clinical pharmacists.<jats:styled-content style="fixed-case">CMM</jats:styled-content>, defined by<jats:styled-content style="fixed-case">ACCP</jats:styled-content>as a core component of the standards of practice for clinical pharmacists, is designed to optimize medication‐related outcomes in collaborative practice environments. New models of care delivery emphasize patient‐centered, team‐based care and increasingly link payment to the achievement of positive economic, clinical, and humanistic outcomes. Hence clinical pharmacists practicing under<jats:styled-content style="fixed-case">CDTM</jats:styled-content>agreements or through other privileging processes are well positioned to provide<jats:styled-content style="fixed-case">CMM</jats:styled-content>. The economic value of clinical pharmacists in team‐based settings is well documented. However, patient access to<jats:styled-content style="fixed-case">CMM</jats:styled-content>remains limited due to lack of payer recognition of the value of clinical pharmacists in collaborative care settings and current health care payment policy. Therefore, the clinical pharmacy discipline must continue to establish and expand its use of<jats:styled-content style="fixed-case">CDTM</jats:styled-content>agreements and other collaborative privileging mechanisms to provide<jats:styled-content style="fixed-case">CMM</jats:styled-content>. Continued growth in the provision of<jats:styled-content style="fixed-case">CMM</jats:styled-content>by appropriately qualified clinical pharmacists in collaborative practice settings will enhance recognition of their positive impact on medication‐related outcomes.</jats:p>